11 results about "Liposome" patented technology

The present invention provides certain cationic lipids containing stigmasterol, ergosterol and cholic acid groups. Compounds of the invention are useful, either alone or in combination with other lipid aggregate-forming components (e.g., DOPE, DOSPA, DOTMA or cholesterol) for formulation into liposomes or other lipid aggregates. Such aggregates are cationic, and able to form stable complexes with anionic macromolecules, such as nucleic acids. The cationic lipids of the invention are useful in methods of transfecting cells, particularly to introduce nucleic acids into cells. The invention also related to kits for the preparation of lipid aggregates and to lipid aggregates and compositions for transfection of cells.

The invention discloses an oxygen-fluorine liposome microbubble therapeutic agent which consists of microbubbles, and oxygen and at least one perfluocarbon existing in the microbubbles, wherein the gas nucleus takes oxygen as a principle component and takes perfluocarbon as an auxiliary component, and the microbubble mainly consists of phospholipid and polyethylene glycol derivative. According to the oxygen-fluorine liposome microbubble therapeutic agent, oxygen can be controlled to be released in a human body through veins delivery and targeted hypoxia tissue under ultrasound wave irradiation, the hypoxia disease is treated, and the therapeutic agent serves as a contrast agent used for ultrasonic enhanced imaging. Therefore, the microbubble is a developing agent and an oxygenating therapeutic agent.

The invention discloses a lung cancer and breast cancer treatment compound preparation containing active ingredients of traditional Chinese medicine and a preparation method of the lung cancer and breast cancer compound preparation. The lung cancer and breast cancer treatment compound preparation is made from erianin, taxol, bufalin and bruceine D according to a certain weight ratio. According to the preparation method, liposomes are prepared according to an ethyl alcohol injection method or dropping pills are prepared by taking polyethylene glycol as a base material to obtain the lung cancer and breast cancer treatment compound preparation containing the active ingredients of the traditional Chinese medicine. The form of the compound preparation is compound liposomes and compound dripping pills. According to animal in-vivo anticancer pharmacological experiments, the lung cancer and breast cancer treatment compound preparation containing the active ingredients of the traditional Chinese medicine has obvious inhibiting effect on growth of lung cancer and breast cancer and has higher anticancer activity than chemotherapeutic drug 5-fluorouracil.

The invention relates to the technical field of hepatitis B virus detection and in particular relates to a kit and a detection method of hepatitis B virus. The kit provided by the invention comprisesa liposome-QD compound marked reporting probe, a magnetic bead modified capturing probe and a buffering solution; a nucleic acid sequence of the reporting probe and a nucleic acid sequence of the capturing probe are complementary with DNA (Deoxyribonucleic Acid) of the hepatitis B virus respectively. According to the kit provided by the invention, quantum dots are covered with liposome so that a fluorescence signal is greatly amplified and concentrated and the detection sensitivity is easy to realize. The kit provided by the invention has the advantages of high detection sensitivity and good specificity, the detection limit is 10fmol and a detection result can be obtained within 1h.

Encapsulated bitter peptides, methods of encapsulating bitter peptides, and nutritional compositions including encapsulated bitter peptides are provided. The bitter peptides can be encapsulated in a hydrophobic matrix, such as an organogel, a solid lipid nanoparticle, a liposome or combinations thereof. The encapsulated bitter peptides can be bioavailable, can be selectively encapsulated such that peptides needed for emulsion stabilization are not encapsulated and can maintain encapsulation during further processing such as heat treatment and homogenization.

Disclosed is a gene recombinant human interferon alpha 2b liposome comprising the following constituents, bean phospholipin 50-150mg, cholesterin 5-50mg, fatty oil 10-200ug, colloid silicon 10-200ug and interferon. By adding the conventional auxiliary materials into the gene recombinant human interferon alpha 2b liposome, the dosage forms of injection, suppository, eye drops, spray and electuary can be obtained.

The invention discloses a cationic macromolecular proteolipid gene medicine carrier, a preparation method and an application, wherein the cationic macromolecular proteolipid gene medicine carrier is a macromolecular transferrin liposome prepared by transferrin-long-chain alkyl quaternary ammonium salt and a lipid ingredient in a mass ratio of (0.05 to 20): 1. The result of a gene transfection experiment indicates that the gene transfection efficiency of the macromolecular transferrin liposome in 293T cells, NIH-3T3 cells, liver cancer Huh-7 cells, SMMC-7721 cells, lung cancer A549 cells is equivalent to the gene transfection efficiency of a positive control, namely a cationic liposome Lipofectamine TM2000. The system of the cationic macromolecular proteolipid gene medicine carrier is good in biocompatibility, low in cytotoxicity, and capable of being used as an excellent non-viral gene medicine delivery carrier.

The present invention provides a composition comprising a sPLA2 hydrolysable liposome, an exterior solution, and an interior solution within the liposome, -wherein the concentration of osmolytes is higher in the interior solution than in the exterior solution. The composition improves storage stability of sPLA2 hydrolysable liposomes, in particular at when stored at 2-8 degrees Celsius. The liposome preferably encapsulates cisplatin. The invention also provides methods of preparing the composition of the invention.